HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Strategy to better select HIV-infected individuals for latent TB treatment in BCG-vaccinated population.

AbstractOBJECTIVE:
To evaluate the T-SPOT.TB interferon-γ releasing assay and the tuberculin skin test (TST), for the diagnosis of latent tuberculosis infection(LTBI) and the development of subsequent active tuberculosis, in BCG-vaccinated HIV-infected individuals.
METHODS:
HIV-infected individuals without clinical suspicion of active TB or a past history of TB were enrolled from 1 January 2008 to 30 November 2010. Both T-SPOT.TB test and TST were offered to the participants whom were followed up prospectively until April 30, 2012 for development of TB.
RESULTS:
Among the 909 participants, 25% had positive TST reactions with cut-off point of 5 mm and 15% had positive T-SPOT.TB results. After a median follow-up of 2.97 years, there were 5 cases developed culture-confirmed active TB (all had dual positive TST and T-SPOT.TB results), and the incidence was 0.17 per 100 person-years. The relative risks (RRs) for subsequent active TB in HIV-infected individuals with positive TST results, positive T-SPOT.TB results and dual positive results compared with the risk for individuals with negative results were 40.6 (95% CI 2.1-767.9), 73.9 (95% CI 3.9-1397.7) and 226.5 (95% CI 12.0-4284), respectively. The number needed to treat to prevent one subsequent TB case among patients with a positive TST, a positive T-SPOT.TB and dual positive results was 35, 22 and 8 respectively.
CONCLUSIONS:
Adopting positive results of the TST and T-SPOT.TB to screen LTBI among BCG-vaccinated HIV-infected individuals might be feasible. Number needed to treat for isoniazid preventive therapy could be reduced significantly by using dual positive strategy.
AuthorsChin-Hui Yang, Pei-Chun Chan, Say-Tsung Liao, Shu-Hsing Cheng, Wing-Wai Wong, Li-Min Huang, Po-Ren Hsueh, Hung-Yi Chiou
JournalPloS one (PLoS One) Vol. 8 Issue 8 Pg. e73069 ( 2013) ISSN: 1932-6203 [Electronic] United States
PMID24015285 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antitubercular Agents
  • Isoniazid
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antitubercular Agents (administration & dosage)
  • Female
  • Follow-Up Studies
  • HIV Infections
  • Humans
  • Isoniazid (administration & dosage)
  • Latent Tuberculosis (diagnosis, drug therapy)
  • Male
  • Middle Aged
  • Mycobacterium bovis
  • Tuberculin Test

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: